Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 73Thoracic 32Gastrointestinal 25Head & Neck 23Breast 23Gynecologic 20Dermatologic 18Sarcoma 7Other solid neoplasm 5NET 2Endocrine 2Lymphoid 1CNS 1

Conditions

Lymphoma 340Lymphoma, Non-Hodgkin 295Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Lymphoma, Large B-Cell, Diffuse 217Leukemia 186Lymphoma, Follicular 183Lymphoma, Mantle-Cell 167Recurrence 141Hodgkin Disease 141Lymphoma, B-Cell 139Leukemia, Myeloid, Acute 133Burkitt Lymphoma 120Lymphoma, B-Cell, Marginal Zone 94Multiple Myeloma 86Myelodysplastic Syndromes 83Waldenstrom Macroglobulinemia 62Lymphoma, T-Cell, Peripheral 56Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Neoplasms 52Lymphoma, T-Cell, Cutaneous 52Hematologic Neoplasms 49Lymphoma, Large-Cell, Anaplastic 43Lymphoma, T-Cell 41Lymphoma, Large-Cell, Immunoblastic 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 40Mycosis Fungoides 38Leukemia, B-Cell 34Sezary Syndrome 30Myeloproliferative Disorders 29

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × Lymphoid × Clear all
NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

RAPT Therapeutics, Inc.

Phase 1/2 Completed
323 enrolled
BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡